Should I Buy KMDA? KMDA 2026 Analysis

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

8.210

1 Day change

2.37%

52 Week Range

9.150

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Good buy right now (pre-market ~8.15): the broader trend is still bullish (SMA_5 > SMA_20 > SMA_200) and the stock is trading near a defined support zone (S1 ~7.96), offering a favorable entry for an impatient buyer.
Near-term upside levels to watch are the pivot (~8.35) and resistance zones at ~8.74 (R1) then ~8.99 (R2); clearing the pivot would improve momentum.
Sentiment skew is constructive: a Buy-rated analyst with a $13 target remains supportive, and options open interest is heavily call-leaning.
No fresh news this week; the next clear catalyst is earnings (2026-02-27 pre-market), which can draw positioning ahead of the event.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Trend structure: Bullish moving average stack (SMA_5 > SMA_20 > SMA_200) suggests the primary trend remains up.
Momentum: MACD histogram -0.0397 and negatively expanding signals a short-term momentum fade/pullback inside that broader uptrend.
RSI_6 at 42.23: mildly weak/neutral (not oversold), implying room for continued chop before a clean rebound.
Key levels: Pivot 8.35 (price below pivot pre-market is slightly bearish near-term). Support S1 7.956 then S2 7.713. Resistance R1 8.743 then R2 8.986.
Pattern-based stats: similar-pattern projection shows modest next-day drift (-0.22%) but stronger next-week expectation (+5.87%), supporting a buy-for-the-weekly-window stance.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: Calls 150 vs puts 12 (OI put/call 0.08) = strongly call-skewed positioning (bullish sentiment).
Volume is extremely thin (today total volume 1 contract), so the volume ratios are not very informative; sentiment is better inferred from open interest than today’s prints.
Volatility: IV_30d 141.49 vs historical vol 40.9 (IV significantly elevated) suggests the market is pricing meaningful uncertainty (often earnings-related).
IV trend: 5D/10D IV averages (159.9/158.2) are above current 30D IV reading, implying IV has been easing recently, but remains high overall.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings ahead: QDEC 2025 earnings scheduled for 2026-02-27 (pre-market) can serve as a near-term positioning catalyst.
- Analyst support: H.C. Wainwright reiterates Buy and raised PT to $13 (up from $11), highlighting focus back on core products.
- Fundamentals (latest reported quarter) show solid YoY growth in revenue, profitability, EPS, and gross margin.
- Options open interest is heavily call-skewed, consistent with bullish positioning.

Neutral/Negative Catalysts

- Short-term momentum is currently soft (MACD histogram below zero and worsening), which can keep the stock capped below the 8.35 pivot in the immediate term.
- No news flow in the past week: lack of fresh catalysts can limit immediate breakout probability.
- Options imply very high volatility (IV far above realized), reflecting elevated uncertainty into upcoming events (even if directionally bullish positioning dominates).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $47.01M, +12.63% YoY (healthy top-line growth).
Net income: $5.30M, +37.10% YoY (profit growth accelerating vs revenue).
EPS: $0.09, +28.57% YoY.
Gross margin: 42.04%, +1.82% YoY (incremental margin improvement supports earnings quality).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2025-12-09: H.C. Wainwright raised price target to $13 from $11 and maintained a Buy rating.
Rationale: discontinuing the Phase 3 inhaled alpha-1 antitrypsin deficiency trial removes an overhang and refocuses KMDA on core products.
Wall Street-style pros: raised target + maintained Buy implies conviction in core business value and improved narrative clarity.
Wall Street-style cons: the discontinued Phase 3 program reduces pipeline optionality and can keep some investors cautious until core products demonstrate sustained growth/trajectory.

2 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is 14 USD with a low forecast of 13 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.020

Low

Averages

High

Current: 8.020

Low

Averages

High

H.C. Wainwright

Buy

maintain

$11 -> $13

AI Analysis

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

AI Analysis

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Benchmark

Robert Wasserman

Strong Buy

Initiates

$15

2025-03-21

Reason

Benchmark

Robert Wasserman

Price Target

$15

2025-03-21

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Kamada with a Buy rating and $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMDA

Unlock Now

KMDA Should I Buy

KMDA Should I Buy

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch